SERA

SERA

Sera Prognostics Inc

Sera Prognostics develops and commercializes blood-based biomarker tests and predictive analytics for women's health, focusing on pregnancy-related conditions. Their flagship product, the PreTRM test, assesses premature birth risk in expectant mothers.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$173today

Score Overview

1 Year
Score
Net Growth-0.66%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-29.63%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.7
Net Growth8.20%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-30.49%
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth8.20%
Net Trend60%
Net Income Consistency
Rev Growth-30.49%
Rev Trend60%
Revenue Consistency

See the full market ranking โ†’

Sera Prognostics Inc fundamental performance

Between 2021 and 2025, revenue declined from $ 82K to $ 81K and net income went from -$ 35M to -$ 31M. Revenue increased in 60% of the years measured; net income in 60%.

Sera Prognostics Inc currently holds a 5-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.02โ€”
1 Year2025-08-12
$ 2.23-9.42%
5 Years2021-08-12
$ 11.70-82.74%
All Time2021-07-15
$ 11.90-83.03%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 57K-$ 32M$ 47M
2025$ 81K-$ 31M$ 39M
2024$ 77K-$ 32M$ 46M
2023$ 306K-$ 36M$ 49M
2022$ 268K-$ 44M$ 82M
IPO2021$ 82K-$ 35M$ 105M

Explore beyond SERA

You're looking at Sera Prognostics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies